Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study - Wikidata - wikimedia - TriplyDB

Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study

Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study

http://www.wikidata.org/entity/Q34554733

about

Reproductive issues in patients undergoing Hematopoietic Stem Cell Transplantation: an update NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report Secondary solid cancer screening following hematopoietic cell transplantation National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Subsequent Neoplasms Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole.Current issues in chronic graft-versus-host disease.Donor-derived second hematologic malignancies after cord blood transplantation.Oral complications of cancer and cancer therapy: from cancer treatment to survivorship.6-Thioguanine and S⁶-methylthioguanine are mutagenic in human cells Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.How I treat late effects in adults after allogeneic stem cell transplantation.Human papillomavirus reactivation following treatment of genital graft-versus-host disease.Oral verruciform xanthoma associated with chronic graft-versus-host disease: a report of five cases and a review of the literature Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia Roles of the immune system in skin cancer.Female long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management.Use of azathioprine for graft-vs-host disease is the major risk for development of secondary malignancies after haematopoietic stem cell transplantation: a nationwide population-based study.Subsequent malignant neoplasms after hematopoietic cell transplantation.Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.Graft-versus-host disease: role of inflammation in the development of chromosomal abnormalities of keratinocytes Impact of chronic GVHD on late complications after hematopoietic cell transplantation.Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party.Second malignancies after autologous hematopoietic cell transplantation in children.DNA damage and repair in epithelium after allogeneic hematopoietic stem cell transplantation Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature.Oral graft-versus-host disease.Solid cancers after allogeneic hematopoietic cell transplantation Adherence to cancer screening guidelines in Australian survivors of allogeneic blood and marrow transplantation (BMT).Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors.Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa.Can routine posttransplant HPV vaccination prevent commonly occurring epithelial cancers after allogeneic stem cell transplantation?Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers.Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease.Secondary malignancies across the age spectrum.Oral cancer after prolonged immunosuppression for multiorgan chronic graft-versus-host disease Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.

P2860

Q28079998-D7BA6EEA-BA73-48DB-92F2-87C3BA0646D1 Q28081289-F4DE0E8E-51D6-4D40-A2E9-4B7B312E8957 Q28088369-0620DDB4-6244-47D0-BAE0-786BF57F1330 Q29248394-32E23E49-2779-4724-9491-B8A2404B2B9A Q33626342-4EEC044C-5AAC-4FF2-9C3C-D7BDF7775DE7 Q33917187-9F337715-EC2C-4FE3-AD8D-FD25F92DF394 Q33952705-D7E1C754-4994-476A-A537-E90B834E278C Q34299445-54E3FDD6-1983-4630-874A-E2CF5C5EF866 Q34440523-AE0EA10A-AD52-49F0-9B07-D45DAF186D8E Q34568905-FFD9DF16-DBF2-4569-8E03-BE732191FF35 Q34707208-9F9212E0-AA93-401D-87CC-AB5CBE546608 Q34741675-5CCAB7FB-7BDD-46D2-894D-DFE816E4900A Q34993495-11AA8D92-CB6B-4755-B63F-9F63225AEA81 Q35023409-FAB11C38-90C5-4E9D-BB90-40071D67B46D Q35036840-3933EC9C-BEE4-42DA-A85B-3B55C4B8BEA7 Q35153813-21F03DD3-940F-4160-8703-E84B7B50C7D9 Q35403714-13F92069-D96B-4DE1-AFD6-68904AC23BE6 Q35671371-DC43B43A-A396-48D2-82BA-AE64D26922F9 Q35677669-0DC1C0E1-08C9-4632-9CC1-F3BA7C55A64D Q35678455-758A5933-BBC2-48CA-9856-CD9F6CF932C6 Q35757247-1222BC46-493F-4B89-B740-54761B606D14 Q36222116-003C1E17-2C04-44B5-AEF3-6EA4201D4D1F Q36270126-6C041728-A4E9-40CD-9FCD-5A9DEEBADA67 Q36384739-536D14C3-7820-4C9B-BCB3-2127436B14B9 Q36476400-9166E1C6-E1F7-41F8-A847-387E6E2BFAB0 Q36538311-688B3C51-2221-49B4-BC97-39959F06E1AC Q36579263-E8FDDF1A-6BC6-4F5E-AE81-5C9C33572E54 Q36783762-B1D82F7D-DDD2-4AB9-AC3C-22F70A8E8ABC Q36925994-0E40CE39-B5FF-4E15-B459-8A85770BEB77 Q36932886-158DB94E-D9E4-4DA5-8372-668FC997E27B Q37082013-8A56302D-E834-4AF2-B073-9DDD4A9DEB63 Q37094966-92C5DBB7-8FD9-4351-96F5-9E23FF5CEADE Q37143051-B435FD2F-3134-4BFD-8FD1-3C8341F35B80 Q37157967-1420B406-1102-4A7E-95B1-2BDCA747D61F Q37285453-E9E607C6-84CA-467C-BC33-292D0944DB29 Q37340443-36C7F543-D961-4377-BFA3-06AC37464782 Q37358453-B4EA9B24-CEA7-4C9D-AAF2-A6D802B69A1F Q37379773-80CA4510-22FF-4BBE-B780-5DBDC7934B55 Q37628627-2036C17E-937F-472E-A8B9-3932394603F4 Q37791005-F9473E8C-8277-41AA-B50C-77497BE95B36

P2860

Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study

http://www.wikidata.org/entity/Q34554733

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Impact of chronic GVHD therapy ...... ternational case-control study

@ast

Impact of chronic GVHD therapy ...... ternational case-control study

@en

Impact of chronic GVHD therapy ...... ternational case-control study

@nl

type

label

Impact of chronic GVHD therapy ...... ternational case-control study

@ast

Impact of chronic GVHD therapy ...... ternational case-control study

@en

Impact of chronic GVHD therapy ...... ternational case-control study

@nl

prefLabel

Impact of chronic GVHD therapy ...... ternational case-control study

@ast

Impact of chronic GVHD therapy ...... ternational case-control study

@en

Impact of chronic GVHD therapy ...... ternational case-control study

@nl

P1433

Q34554733-B143F05C-E285-4341-BEEC-F6002ADD5922

P1476

Q34554733-9B2E62BC-E0CF-4DE6-89EA-657C170DAA46

P2093

Q34554733-1E3BF8D9-FABC-47E3-A172-012204E91FF8

Q34554733-39D048CE-A6FF-44BA-A518-2BE71095D7E9

Q34554733-6336257C-35CB-469A-9F54-F18A2F0DBA98

Q34554733-9D1B7CAE-F54A-4BB0-8F0F-9283C088929F

Q34554733-AC6CCBD9-D378-4430-B403-FC1D93F8C18A

Q34554733-DDD01D85-EE16-40B0-B37C-0FCC857A9572

Q34554733-E5186E09-91F0-4868-B627-E207F76AE1DD

Q34554733-E66A7115-F4AC-450D-9FD3-195E1D9DAFF3

P2860

Q34554733-020F59ED-B5CA-4FDD-865E-AE2F131810C4

Q34554733-08D65DFD-2750-498F-8B6E-7B056215F931

Q34554733-11C19B0B-0D51-4C4D-90D4-57AA34B29BC4

Q34554733-17D2D07B-7161-4C35-8C16-01D6701FA271

Q34554733-2C71B04B-5E77-46DA-B08A-013497E933BE

Q34554733-3199AB7D-A174-49C9-B5DE-8BB59D283968

Q34554733-328C46D9-FA3F-4C96-B937-07346EFE4BDB

Q34554733-4225BE97-68A4-4884-B3C6-CED0697C2119

Q34554733-588CF25A-14D1-4B4B-9930-620BE0A61770

Q34554733-5B50C26D-84D0-4BBE-8AAC-3A9F49574ED2

P304

Q34554733-912B3EB0-4593-4EF7-BB9C-84B8BC369131

P31

Q34554733-7166C097-A2B9-4255-ACA0-C968662DA346

P356

Q34554733-CD66C021-1E26-48B9-B0CA-64F56B0FE75A

P407

Q34554733-F9B40E8A-ADD2-4BF4-A9A1-9DE938A29185

P433

Q34554733-7AF04D9A-68E5-4AB5-8296-47EE66CCC3C7

P478

Q34554733-2BBF573F-E6CC-4337-AFBB-A5F775B63F07

P50

Q34554733-8093BFAC-0020-4B61-93EC-3E4D17DE4353

Q34554733-8B82DF55-156B-4880-88EB-5E03E3115558

P577

Q34554733-7DCDC839-8CE0-4090-9EBB-B73570CD2ED8

P5875

Q34554733-AD3FEA89-6493-4E8F-A366-6C7CEC38D12B

P698

Q34554733-62A8B34B-3B87-4D83-92C2-B808D5F0513B

P932

Q34554733-1519B5C1-D1A3-4CF9-92D2-23B7E87F37F7

P356

BLOOD-2004-09-3411

P1433

P1476

Impact of chronic GVHD therapy ...... ternational case-control study

@en

P2093

Catherine Metayer

http://www.w3.org/2001/XMLSchema#string

J Douglas Rizzo

http://www.w3.org/2001/XMLSchema#string

Kathleen A Sobocinski

http://www.w3.org/2001/XMLSchema#string

Lois B Travis

http://www.w3.org/2001/XMLSchema#string

Mary E D Flowers

http://www.w3.org/2001/XMLSchema#string

Mary M Horowitz

http://www.w3.org/2001/XMLSchema#string

Rochelle E Curtis

http://www.w3.org/2001/XMLSchema#string

William D Travis

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation and cancer

Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens.

Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems.

Skin cancers after organ transplantation.

Chronic inflammation as inductor of pro-cancer microenvironment: pathogenesis of dysregulated feedback control.

Cancer risk following organ transplantation: a nationwide cohort study in Sweden.

HPV infections and immunosuppression.

P304

3802-3811

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2004-09-3411

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Hans Joachim Deeg

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8045751

http://www.w3.org/2001/XMLSchema#string

P698

15687239

http://www.w3.org/2001/XMLSchema#string

P932

1895092

http://www.w3.org/2001/XMLSchema#string